<sup>18</sup>F-FDG PET/CT在食管癌放疗中的应用

谢彦婷; 郑容; 谢彦婷; 郑容

doi:10.3760/cma.j.issn.1673-4114.2013.01.012

[1]

Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer, 2005, 103(1): 148-156.

[2]

Tanabe S, Naomoto Y, Shirakawa Y, et al. F-18 FDG PET/CT contributes to more accurate detection of lymph nodal metastasis from actively proliferating esophageal squamous cell carcinoma. Clin Nucl Med, 2011, 36(10): 854-859. doi: 10.1097/RLU.0b013e318217adc9

[3]

Hsu WH, Hsu PK, Wang SJ, et al. Positron emission tomography- tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg, 2009, 87(5): 1564-1568. doi: 10.1016/j.athoracsur.2009.02.065

[4]

Schröder W, Baldus SE, Mönig SP, et al. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg, 2002, 26(5): 584-587. doi: 10.1007/s00268-001-0271-5

[5]

van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer, 2008, 98(3): 547-557. doi: 10.1038/sj.bjc.6604200

[6]

van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol, 2004, 22(18): 3805-3812. doi: 10.1200/JCO.2004.01.083

[7]

Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med, 2006, 47(8): 1255-1259.

[8]

Schreurs LM, Pultrum BB, Koopmans KP, et al. Better assessment of nodal metastases by PET/CT fusion compared to side-by-side PET/CT in oesophageal cancer. Anticancer Res, 2008, 28(3B): 1867-1873.

[9]

Kato H, Kimura H, Nakajima M, et al. The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer. Oncol Rep, 2008, 20(4): 857-862.

[10]

Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol, 2000, 18(18): 3202-3210. doi: 10.1200/JCO.2000.18.18.3202

[11]

Gillies RS, Middleton MR, Maynard ND, et al. Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/ tomography in the staging of oesophageal cancer. Eur Radiol, 2011, 21(2): 274-280.

[12]

Okada M, Murakami T, Kumano S, et al. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med, 2009, 23(1): 73-80.

[13]

Moureau-Zabotto L, Touboul E, Lerouge D, et al. Impact of CT and ¹⁸F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys, 2005, 63(2): 340-345. doi: 10.1016/j.ijrobp.2005.02.039

[14]

郭洪波, 于金明, 张百江, 等.氟脱氧葡萄糖PET-CT确定食管癌淋巴结放疗靶区的可行性研究.中华放射肿瘤学杂志, 2007, 16(1): 10-14. doi: 10.3760/j.issn:1004-4221.2007.01.003

[15]

Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/ tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2007, 67(1): 187-195. doi: 10.1016/j.ijrobp.2006.09.033

[16]

Hong TS, Killoran JH, Mamede M, et al. Impact of manual and automated interpretation of fused PET/CT data on esophageal target definitions in radiation planning. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1612-1618. doi: 10.1016/j.ijrobp.2008.07.061

[17]

Muijs CT, Schreurs LM, Busz DM, et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol, 2009, 93(3): 447-453.

[18]

Schreurs LM, Busz DM, Paardekooper GM, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition. Dis Esophagus, 2010, 23(6): 493-501. doi: 10.1111/j.1442-2050.2009.01044.x

[19]

Zhong X, Yu J, Zhang B, et al. Using ¹⁸F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys, 2009, 73(1): 136-141. doi: 10.1016/j.ijrobp.2008.04.015

[20]

Yu W, Fu XL, Zhang YJ, et al. GTV spatial conformity between different delineation methods by ¹⁸FDG PET/CT and pathology in esophageal cancer. Radiother Oncol, 2009, 93(3): 441-446.

[21]

Han D, Yu J, Yu Y, et al. Comparison of ¹⁸F-fluorothymidine and ¹⁸F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys, 2010, 76(4): 1235-1241. doi: 10.1016/j.ijrobp.2009.07.1681

[22]

Jeganathan R, McGuigan J, Campbell F, et al. Does pre-operative estimation of oesophageal tumour metabolic length using ¹⁸F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?. Eur J Nucl Med Mol Imaging, 2011, 38(4): 656-662. doi: 10.1007/s00259-010-1670-3

[23]

Westerterp M, Omloo JM, Sloof GW, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia, 2006, 22(2): 149-160. doi: 10.1080/02656730500513523

[24]

Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer, 2007, 109(1): 125-134.

[25]

Roedl JB, Harisinghani MG, Colen RR, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography- tomography. Ann Thorac Surg, 2008, 86(4): 1131-1138. doi: 10.1016/j.athoracsur.2008.05.019

[26]

Klaeser B, Nitzsche E, Schuller JC, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial(SAKK 75/02). Onkologie, 2009, 32(12): 724-730. doi: 10.1159/000251842

[27]

Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with[¹⁸F]fluorodeoxyglucose positron emission tomography(FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol, 2010, 28(31): 4714-4721. doi: 10.1200/JCO.2010.30.7702

[28]

Brown C, Howes B, Jamieson GG, et al. Accuracy of PET/CT in predicting survival in patients with esophageal cancer. World J Surg, 2012, 36(5): 1089-1095. doi: 10.1007/s00268-012-1470-y

[29]

朱婉琦, 于金明, 孙晓蓉, 等. FDG PET/CT代谢体积对食管癌术后预后的预测价值.中华核医学杂志, 2011, 31(6): 378-381. doi: 10.3760/cma.j.issn.0253-9780.2011.06.007

[30]

Guo H, Zhu H, Xi Y, et al. Diagnostic and prognostic value of ¹⁸F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med, 2007, 48(8): 1251-1258. doi: 10.2967/jnumed.106.036509